Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 mRNA LNP vaccine
- Development stage
- Phase 1
- Lead developer
- Sun Yat-sen University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PD-1 mRNA LNP vaccine is an investigational mRNA-based immunotherapy designed as a checkpoint vaccine. Unlike traditional mRNA vaccines that target tumor-associated antigens, this candidate utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding the programmed cell death protein 1 (PD-1). By presenting the PD-1 protein as an immunogen, the vaccine aims to stimulate the patient's own immune system to generate high-affinity endogenous antibodies or T-cell responses against the PD-1 receptor. This approach facilitates a form of active checkpoint inhibition, potentially overcoming limitations of exogenous monoclonal antibodies such as the need for frequent dosing and high systemic peaks. It is currently being evaluated for its safety, immunogenicity, and preliminary efficacy in patients with advanced cancers, specifically primary hepatocellular carcinoma (HCC).
- Other names
- PD-1 mRNA-LNPPD1 mRNA-LNPPD 1 mRNA-LNPPD-1 mRNA vaccinePD1 mRNA vaccinePD 1 mRNA vaccine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD-1 mRNA LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 mRNA LNP vaccine.